Antibodies for the bioanalysis and drug monitoring of ramucirumab

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug ramucirumab (Cyramza) using our range of ready-made anti-idiotypic antibodies.

  • Highly specific to ramucirumab and the ramucirumab/VEGFR2 complex
  • Inhibitory and non-inhibitory antibodies to ramucirumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal derived antibodies, reducing the use of animals in science

Table 1. Antibodies specific to ramucirumab

Specificity

Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Ramucirumab

Inhibitory

Type 1

HCA407

AbD51672ia

hIgG1

<0.1

ADA Control

Order HCA407

HCA408

AbD53006ia

hIgG1

0.8

ADA Control

Order HCA408

HCA409

AbD53014ia

hIgG1

1.4

ADA Control

Order HCA409

TZA050

AbD51673ad

Fab-F-Spy2-H1

0.3

PK bridging ELISA (capture)

Order TZA050

TZA051

AbD51668ad

Fab-F-Spy2-H1

1

PK bridging ELISA (detection)

Order TZA051

TZA051P

AbD51668pap

Fab2-FH-X22-HRP2

1

PK bridging ELISA (detection)

Order TZA051P

Ramucirumab &

Ramucirumab / VEGFR2

Non Inhibitory Type 2

TZA052

AbD53018ad

Fab-F-Spy2-H1

17

PK bridging ELISA (detection)

Order TZA052

TZA052P

AbD53018pap

Fab2-FH-X22-HRP2

17

PK bridging ELISA (detection)

Order TZA052P

Ramucirumab / VEGFR2 Complex Specific

Type 3

TZA053

AbD53034ad

Fab-F-Spy2-H1

1

PK antigen capture ELISA

Order TZA053

TZA053P

AbD53034pap

Fab2-FH-X22-HRP2

1

PK antigen capture ELISA

Order TZA053P

* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2 and (H) His6 tags.
2 Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher


Anti-Ramucirumab Inhibitory Antibodies (Type 1)

The Type 1 anti-ramucirumab antibodies inhibit the binding of the drug ramucirumab to its target, the vascular endothelial growth factor receptor 2 (VEGFR2). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format, they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.


Anti-Ramucirumab Non-Inhibitory Antibody (Type 2)

The type 2 anti-ramucirumab antibody binds to the ramucirumab idiotope but does not inhibit the binding of ramucirumab to VEGFR2. It can therefore be used in combination with a type 1 antibody in a PK bridging ELISA to measure free and partially bound drug.


Anti-Ramucirumab/VEGFR2 Complex-Specific Antibodies (Type 3)

The Type 3 antibody specifically recognizes the drug-target complex, detecting ramucirumab only when it is bound to VEGFR2. It is suitable as a detection antibody in a PK antigen capture assay.


ELISA Protocols to Get You Started

PK Bridging ELISA


Fig. 1. Ramucirumab PK bridging ELISA using antibodies TZA050 and TZA051P

Fig. 1. Ramucirumab PK bridging ELISA using antibodies TZA050 and TZA051P.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.



Fig. 2. Ramucirumab PK bridging ELISA using antibodies TZA050 and TZA052P

 

Fig. 2. Ramucirumab PK bridging ELISA using antibodies TZA050 and TZA052P

Schematic image of PK bridging ELISA measuring free and partially bound drug

Schematic image of PK bridging ELISA measuring free and partially bound drug. Type 1 anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), drug target (red), type 2 anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


PK Antigen capture ELISA

Fig. 3. Ramucirumab PK antigen capture ELISA using antibody TZA053P.

Fig. 3. Ramucirumab PK antigen capture ELISA using antibody TZA053P.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug target complex detection antibody, monovalent Fab format (purple), labeled with HRP.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug target complex detection antibody, monovalent Fab format (purple), labeled with HRP.


ADA Bridging ELISA


Fig. 4. Ramucirumab ADA bridging ELISA using antibody HCA407, HCA408 and HCA409.

 

Fig. 4. Ramucirumab ADA bridging ELISA using antibody HCA407, HCA408 and HCA409.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.